



ANEXA 1

**STANDARDE MINIMALE NECESARE ȘI OBLIGATORII PENTRU
OBTINEREA ATESTATUTUL DE ABILITARE
ÎN CADRUL IOSUD UMF IAȘI**

Conform

1. Ordinului ministrului educației naționale și cercetării științifice nr. 6.129/2016 privind aprobarea standardelor minime necesare și obligatorii pentru conferirea titlurilor didactice din învățământul superior
2. Metodologiei privind organizarea și desfășurarea procesului de obținere a atestatului de abilitare în IOSUD - UMF IAȘI

1. STANDARD MINIMAL ARTICOLE ISI AUTOR PRINCIPAL*

*calitatea de autor principal este atribuită pentru primul autor, ultimul autor, autorul corespondent, sau alți autori a căror contribuție este indicată explicit în cadrul publicației a fi egală cu contribuție primului autor sau a autorului corespondent

Domeniul Medicină, Farmacie: 10 articole, publicate pe parcursul întregii activități

RAPORTARE ARTICOLE ISI AUTOR PRINCIPAL

(listă, cu link-urile corespunzătoare pentru verificare, active)

1. **Antoniou SA**, Buculei I, , Mihaltan F, Crisan Dabija R, Trofor A. Pharmacological strategies for smoking cessation in patients with chronic obstructive pulmonary disease: a pragmatic review. Expert Opin Pharmacother 2020 Early access, **IF pentru 2019=2.87**.
Link catre articolul raportat in revista

<https://www.tandfonline.com/doi/abs/10.1080/14656566.2020.1858796?journalCode=ieop20>

Link catre articolul raportat in format pdf

[Smoking cessation](#)

2. Alexa T, **Antoniou SA (autor corespondent)**, Alexa I, Ilie A, Marinca M, Gafton B, Stefaniu R. Checkpoint inhibitors in NSCLC for the elderly: current challenges and perspectives. Expert Review of Anticancer Therapy 2020 Early access, **IF pentru 2019=3.57**
Link catre articolul raportat in revista

<https://www.tandfonline.com/doi/abs/10.1080/14737140.2021.1852933?journalCode=ier20>

Link catre articolul raportat in format pdf

[Checkpoint inhibitors](#)

3. **Antoniou SA**, Rajnoveanu R, Grigore M, Antohe I. Pharmacotherapy options in pulmonary alveolar proteinosis. *Expert Opin Pharmacother* 2020 21(11): 1359-66. **IF pentru 2019=2,87**
 Link catre articolul raportat in revista
<https://www.tandfonline.com/doi/abs/10.1080/14656566.2020.1757650?journalCode=i eop20>
 Link catre articolul raportat in format pdf
[Pulmonary alveolar proteinosis](#)
4. **Antoniou SA**, Rajnoveanu R, Ulmeanu R, Mihaltan F, Grigore M. Evaluating revefenacin as a therapeutic option for chronic obstructive pulmonary disease. *Expert Opin Pharmacother* 2020 21(9): 997-1004. **IF pentru 2019=2,87**
 Link catre articolul raportat in revista
<https://www.tandfonline.com/doi/abs/10.1080/14656566.2020.1745185>
 Link catre articolul raportat in format pdf
[Revefenacin](#)
5. **Antoniou SA**, Apostol A, Boiculese, LV. Extra-respiratory symptoms in patients hospitalized for a COPD exacerbation: Prevalence, clinical burden and their impact on functional status. *Clinical Respiratory Journal* 2019 13(12):735-40, **IF=1.514**
 Link catre articolul raportat in revista
<https://onlinelibrary.wiley.com/doi/abs/10.1111/crj.13083>
 link catre articolul raportat in format pdf
[Extrarespiratory symptoms](#)
6. **Antoniou SA**. Investigational inhaled therapies for non-CF bronchiectasis. *Expert Opin Investig Drugs*. 2018 Feb;27(2):139-146, **IF=4.03**
 Link catre articolul raportat in revista
<https://www.tandfonline.com/doi/abs/10.1080/13543784.2018.1427728?journalCode=i eid20>
 Link catre articolul raportat in format pdf
[Investigational inhaled therapies](#)
7. **Antoniou SA**. Benralizumab as a potential treatment of asthma. *Expert Biol Ther*. 2017 Jul;17(7):895-900, **IF =3.97**
 Link catre articolul raportat in revista
<https://www.tandfonline.com/doi/abs/10.1080/14712598.2017.1319471?journalCode=i ebt20>
 Link catre articolul raportat in format pdf
[Benralizumab](#)
8. **Antoniou SA**. Lebrikizumab for the treatment of asthma. *Expert Opin Investig Drugs*. 2016 Oct;25(10):1239-49, **IF=4.03**
 Link catre articolul raportat in revista
<https://www.tandfonline.com/doi/abs/10.1080/13543784.2016.1227319?journalCode=i eid20>
 Link catre articolul raportat in format pdf
[Lebrikizumab](#)
9. **Antoniou SA**, Boiculese LV. Palliative care outcome measures in COPD patients: a conceptual review. *Expert Rev Pharmacoecon Outcomes Res*. 2016;16(2):267-74. **IF=1.78**
 Link catre articolul raportat in revista
<https://www.tandfonline.com/doi/abs/10.1586/14737167.2016.1162714?journalCode=i erp20>
 Link catre articolul raportat in format pdf
[Palliative care outcome](#)

10. **Antoniou SA**, Petrescu E, Stanescu R, Anisie E, Boiculese L. Impact of fatigue in patients with chronic obstructive pulmonary disease: results from an exploratory study. *Ther Adv Respir Dis*. 2016 Feb;10(1):26-33. **IF=2.74**
Link catre articolul raportat in revista
https://journals.sagepub.com/doi/10.1177/1753465815617707?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%20pubmed
Link catre articolul raportat in format pdf
[Impact fatigue](#)
11. Ulmeanu R, Antohe I, Anisie E, **Antoniou SA**. Nivolumab for advanced non-small lung cancer therapy: an evaluation of a phase III study. *Expert Review of Anticancer Therapy* 2016,16(2):165-167, **IF=2.21**
Link catre articolul publicat in revista
<https://www.tandfonline.com/doi/abs/10.1586/14737140.2016.1127760?journalCode=ier20>
Link catre articolul raportat in format pdf
[Nivolumab for advanced non-small lung cancer](#)
12. **Antoniou S**. Novel inhaled combined antibiotic formulations in the treatment of *Pseudomonas aeruginosa* airways infections in cystic fibrosis. *Expert Rev Anti Infect Ther*. 2015 Jul;13(7):897-905., **IF=3.54**
Link catre articolul raportat in revista
<https://www.tandfonline.com/doi/abs/10.1586/14787210.2015.1041925?journalCode=ierz20>
Link catre articolul raportat in format pdf
[Combined Inhaled antibiotic](#)
13. **Antoniou SA**, Ungureanu D. Measuring fatigue as a symptom in COPD: From descriptors and questionnaires to the importance of the problem. *Chron Respir Dis*. 2015 Aug;12(3):179-88. **IF=1.64**
Link catre articolul raportat in revista
https://journals.sagepub.com/doi/10.1177/1479972315575716?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%20pubmed
Link catre articolul raportat in format pdf
[Measuring fatigue](#)
14. **Antoniou SA**. Targeting 5-lipoxygenase-activating protein in asthma and chronic obstructive pulmonary disease. *Expert Opin Ther Targets*. 2014 Nov;18(11):1285-92. **IF=5.13**
Link catre articolul raportat in revista
<https://www.tandfonline.com/doi/abs/10.1517/14728222.2014.945425?journalCode=iet20>
Link catre articolul raportat in format pdf
[Targeting 5-lipoxygenase-activating protein](#)
15. Mihălțan FD, **Antoniou SA**, Ulmeanu R. Asthma and pregnancy: therapeutic challenges. *Arch Gynecol Obstet*. 2014 Oct;290(4):621-7. **IF=1.36**
Link catre articolul raportat in revista
<https://link.springer.com/article/10.1007/s00404-014-3342-1>
Link catre articolul raportat in format pdf
[Asthma and pregnancy](#)
16. **Antoniou S**. Bedoradrine for treating asthma and chronic obstructive pulmonary disease. *Expert Opin Investig Drugs*. 2014 Aug;23(8):1149-56, **IF=5.52**
Link catre articolul raportat in revista
<https://www.tandfonline.com/doi/abs/10.1517/13543784.2014.928284?journalCode=ieid20>

- Link catre articolul raportat in format pdf
[Bedoradrine for treating asthma](#)
17. **Antoniou SA**, Dimofte G, Ungureanu D. Immune therapies for malignant mesothelioma. Expert Rev Anticancer Ther. 2014 Aug;14(8):965-73. **IF=2.24**
Link catre articolul raportat in revista
<https://www.tandfonline.com/doi/abs/10.1586/14737140.2014.919859?journalCode=iery20>
Link catre articolul raportat in format pdf
[Immune therapies for mesothelioma](#)
18. **Antoniou S**. Epratuzumab for systemic lupus erythematosus. Expert Opin Biol Ther. 2014 Jul;14(7):1045-7. **IF=3.74**
Link catre articolul raportat in revista
<https://www.tandfonline.com/doi/abs/10.1080/1744666X.2018.1450141?journalCode=iery20>
Link catre articolul raportat in format pdf
[Epratuzumab for lupus](#)
19. **Antoniou SA**, Mihaltan F. Outcome measures for palliative oxygen therapy: relevance and practical utility. Expert Rev Pharmacoecon Outcomes Res. 2014 Jun;14(3):417-23, **IF=1.66**
Link catre articolul raportat in revista
<https://www.tandfonline.com/doi/abs/10.1586/14737167.2014.906308?journalCode=ierp20>
Link catre articolul raportat in format pdf
[Outcome measures for palliative oxygen](#)
20. **Antoniou SA**, Puiu A, Zaharia B, Azoicai D. Health status during hospitalisations for chronic obstructive pulmonary disease exacerbations: the validity of the Clinical COPD Questionnaire. Expert Rev Pharmacoecon Outcomes Res. 2014 Apr;14(2):283-7. **IF=1.66**
Link catre articolul raportat in revista
<https://www.tandfonline.com/doi/abs/10.1586/14737167.2014.887446?journalCode=ierp20>
Link catre articolul raportat in format pdf
[Health status during hospitalisations](#)
21. **Antoniou S**. Outpatient palliative care effectiveness: both patients and caregivers can gain. Expert Rev Pharmacoecon Outcomes Res. 2013 Oct;13(5):575-7. **IF=1.87**
Link catre articolul raportat in revista
<https://www.tandfonline.com/doi/abs/10.1586/14737167.2013.833060?journalCode=ierp20>
Link catre articolul raportat in format pdf
[Outpatient palliative care](#)
22. **Antoniou SA**. Discontinued drugs for pulmonary, allergy, gastrointestinal, arthritis (2012). Expert Opin Investig Drugs. 2013 Nov;22(11):1453-64, **IF= 5.43**
Link catre articolul raportat in revista
<https://www.tandfonline.com/doi/abs/10.1517/13543784.2013.836489?journalCode=ieid20>
Link catre articolul raportat in format pdf
[Discontinued drugs for pulmonary, allergy](#)
23. **Antoniou SA**, Carone M. Hospitalizations for chronic obstructive pulmonary disease exacerbations and their impact on disease and subsequent morbidity and mortality. Expert Rev Pharmacoecon Outcomes Res. 2013 Apr;13(2):187-9. **IF=1.87**
Link catre articolul publicat in revista
<https://www.tandfonline.com/doi/abs/10.1586/erp.13.9?journalCode=ierp20>
Link catre articolul publicat in format pdf
[Hospitalisations COPD](#)

24. **Antoniou S**, Azoicai D. Ciprofloxacin DPI in non-cystic fibrosis bronchiectasis: a Phase II randomized study. Expert Opin Investig Drugs. 2013 May;22(5):671-3, **IF=5.43**
Link catre articolul raportat in revista
<https://www.tandfonline.com/doi/abs/10.1517/13543784.2013.783565?journalCode=iei d20>
Link catre articolul raportat in format pdf
[Ciprofloxacin DPI in non-cystic fibrosis bronchiectasis](#)
25. **Antoniou SA**, Antohe I. Evaluation of inhaled tiotropium in asthma, uncontrolled with standard combination therapy. Expert Opin Pharmacother. 2013 May;14(7):967-9. **IF=3.08**
Link catre articolul raportat in revista
<https://www.tandfonline.com/doi/abs/10.1517/14656566.2013.783015?journalCode=ie op20>
Link catre articolul raportat in format pdf
[Evaluation of inhaled tiotropium in asthma](#)
26. **Antoniou SA**. Monoclonal antibodies for asthma and chronic obstructive pulmonary disease. Expert Opin Biol Ther. 2013 Feb;13(2):257-68. **IF=3.65**,
Link catre articolul raportat in revista
<https://www.sciencedirect.com/science/article/pii/S0163725816301954?via%3Dihub>
Link catre articolul raportat in format pdf
[Monoclonal antibodies for asthma and COPD](#)
27. Antohe I, Croitoru R, **Antoniou S**. Tralokinumab for uncontrolled asthma. Expert Opin Biol Ther. 2013 Feb;13(2):323-6. **IF=3.65**
Link catre articolul raportat in revista
<https://www.tandfonline.com/doi/abs/10.1517/14712598.2012.748740?journalCode=ie bt20>
Link catre articolul raportat in format pdf
[Tralokinumab in asthma](#)
28. Azoicai D, **Antoniou SA**. MP-376 (Aeroquin) for chronic Pseudomonas aeruginosa infections. Expert Opin Investig Drugs. 2013 Feb;22(2):267-76, **IF=5.43**
Link catre articolul publicat in revista
<https://www.tandfonline.com/doi/abs/10.1517/13543784.2013.748034?journalCode=iei d20>
Link catre articolul publicat in format pdf
[Aeroquin for Pseudomonas aeruginosa](#)
29. **Antoniou SA**. Targeting PDGF pathway in pulmonary arterial hypertension. Expert Opin Ther Targets. 2012 Nov;16(11):1055-63. **IF: 4.13**
Link catre articolul publicat in revista
<https://www.tandfonline.com/doi/abs/10.1517/14728222.2012.719500?journalCode=iet t20v>
Link catre articolul publicat in format pdf
[Targeting PDGF PAH](#)
30. **Antoniou SA**. Discontinued drugs 2011: pulmonary, allergy, gastrointestinal and arthritis. Expert Opin Investig Drugs. 2012 Nov;21(11):1607-18, **IF=4.74**
Link catre articolul raportat in revista
<https://www.tandfonline.com/doi/abs/10.1517/13543784.2012.712112?journalCode=iei d20>
Link catre articolul raportat in format pdf
[Discontinued drugs 2011](#)

- 31. Antoniu SA.** Targeting RhoA/ROCK pathway in pulmonary arterial hypertension. Expert Opin Ther Targets 2012 16(4): 355-363, **IF: 4.13**
Link catre articolul raportat in revista
<https://www.tandfonline.com/doi/abs/10.1517/14728222.2012.671811?journalCode=iet20>
Link catre articolul raportat in format pdf
[Targeting RhoAROCK](#)
- 32. Antoniu SA, Cojocaru I.** Inhaled colistin for lower respiratory tract infections. Expert Opin Drug Deliv 2012 9(3): 333-342, **IF: 4.86**
Link catre articolul raportat in revista
<https://www.tandfonline.com/doi/abs/10.1517/17425247.2012.660480?journalCode=iedd20>
Link catre articolul raportat in format pdf
[Inhaled colistin](#)
- 33. Antoniu SA, Trofor, AC.** Varenicline for smoking cessation intervention in chronic obstructive pulmonary disease. Expert Opin Pharmacother 2011 12(16): 2595-2597
Impact factor 3.20
Link catre articolul raportat in revista
<https://www.tandfonline.com/doi/abs/10.1517/14656566.2011.605786?journalCode=ieop20>
Link catre articolul raportat in format pdf
[Varenicline for smoking cessation](#)
- 34. Antoniu SA.** Discontinued drugs 2010: rheumatology, allergy and dermatology, pulmonary. Expert Opin Investig Drugs 2011 20(9): 1175-1187, **IF= 5.27**
Link catre articolul raportat in revista
<https://www.tandfonline.com/doi/abs/10.1517/13543784.2011.599800?journalCode=ieid20>
Link catre articolul raportat in format pdf
[Discontinued drugs 2010](#)
- 35. Antoniu SA.** Therapeutic approaches in hereditary angioedema. Clin Rev Allergy Immunol 2011 41(1):114-122 **IF= 3.43**
Link pentru articolul raportat in revista
<https://link.springer.com/article/10.1007%2Fs12016-011-8254-2>
Link pentru articolul raportat in format pdf
[Therapeutic approaches angioedema](#)
- 36. Antoniu SA, Trofor AC.** Inhaled gentamicin in non-cystic fibrosis bronchiectasis: effects of long-term therapy. Expert Opin Pharmacother 2011 12(7): 1191-1194 **IF=3.20**
Link catre articolul raportat in revista
<https://www.tandfonline.com/doi/abs/10.1517/14656566.2011.563735?journalCode=ieop20>
Link catre articolul raportat in format pdf
[Inhaled gentamicin](#)
- 37. Antoniu SA, Sampablo I, Carone M.** Tiotropium in the treatment of asthma. Expert Opin Pharmacother. 2011 12(3): 489-491 **IF= 3.20**

Link catre articolul raportat in revista

<https://www.tandfonline.com/doi/abs/10.1517/14656566.2011.545054>

Link catre articolul raportat in format pdf

[Tiotropium in asthma](#)

- 38. Antoniu SA,** Carone M, Sampablo I. Triple inhaled therapy in stable chronic obstructive pulmonary disease: the earlier the better ? Expert Opin Pharmacother 2010 11(6):1039-1042 **IF= 2.40**

Link catre articolul raportat in revista

<https://www.tandfonline.com/doi/abs/10.1517/14656566.2010.1003652450?journalCode=ieop20>

Link catre articolul raportat in format pdf

[Triple inhaled COPD earlier](#)

- 39. Antoniu SA,** Cojocaru I. Pitrakinra for asthma. Expert Opin Biol Ther 2010 10(11):1609-1615 **IF= 3.27**

Link catre articolul raportat in revista

<https://www.tandfonline.com/doi/abs/10.1517/14712598.2010.524203?journalCode=iebt20>

Link catre articolul raportat in format pdf

[Pitrakinra for asthma](#)

- 40. Antoniu SA.** GM-CSF pathway correction in pulmonary alveolar proteinosis. Expert Opin Biol Ther. 2010 10(9):1357- 1365 **IF= 3.27**

Link catre articolul raportat in revista

<https://www.tandfonline.com/doi/abs/10.1517/14712598.2010.510507?journalCode=iebt20>

Link catre articolul raportat in format pdf

[GM-CSF in PAP](#)

- 41. Antoniu SA.** Targeting the TNF-alpha pathway in sarcoidosis. Expert Opin Ther Targets 2010 14(1):21-9 **IF= 3.64,**

Link catre articolul raportat in revista

<https://www.tandfonline.com/doi/abs/10.1517/14728220903449244?journalCode=iett20>

Link catre articolul raportat in format pdf

[Targeting TNF sarcoidosis](#)

- 42. Antoniu SA.** Effects of inhaled therapy on biomarkers of systemic inflammation in stable chronic obstructive pulmonary disease. Biomarkers 2010 15(2): 97-103 **IF= 2.09**

Link catre articolul raportat in revista

<https://www.tandfonline.com/doi/abs/10.3109/13547500903311902?journalCode=ibmk20>

Link catre articolul raportat in format pdf

[BiomarkersCOPD](#)

- 43. Antoniu SA.** Novel therapies for hypereosinophilic syndromes. Neth J Med 2010 68(1):304-10 **IF= 1.84**

Link catre articolul raportat in revista

<http://www.njmonline.nl/article.php?a=945&d=607&i=129>

Link catre articolul raportat in format pdf

[Novel therapies for hypereosinophilic](#)

44. **Antoniou SA.** Fudosteine effects on mucin production Evaluation of: Rhee CK, Kang CM, You MB, et al. Expert Opin Investig Drugs 2009 18(1): 105-107, [IF=4.21](#)

Link catre articolul raportat in revista

<https://www.tandfonline.com/doi/abs/10.1517/13543780802623863?journalCode=ieid20>

Link catre articolul raportat in format pdf

[Fudosteine effects on mucin production](#)

45. **Antoniou SA.** Discontinued drugs 2008: pulmonary and allergy. Expert Opin Investig Drugs 2009 18(12):1799-1805, [IF= 4.21](#)

Link catre articolul raportat in revista

<https://www.tandfonline.com/doi/abs/10.1517/13543780903320591>

Link catre articolul raportat in format pdf

[Discontinued drugs 2008](#)

46. **Antoniou SA.** Daclizumab a novel corticosteroid-sparing therapy for asthma ? Expert Opin Investig Drugs. 2009 18(3): 369-371, [IF= 4.21](#)

Link catre articolul raportat in revista

<https://www.tandfonline.com/doi/abs/10.1517/13543780802688882?journalCode=ieid20>

Link catre articolul raportat in format pdf

[Daclizumab asthma](#)

47. **Antoniou SA.** Itraconazole for severe asthma with fungal sensitivity. Expert Opin Pharmacother. 2009 10(7):1231-1233 [IF= 2.01](#)

Link catre articolul raportat in revista

<https://www.tandfonline.com/doi/abs/10.1517/14656560902918319?journalCode=ieop20>

Link catre articolul raportat in format pdf

[Itraconazole for severe asthma](#)

48. **Antoniou SA.** Cytokine antagonists for the treatment of asthma: progress to date. BioDrugs 2009; 23(4): 241-251 [IF= 3.5](#)

Link catre articolul raportat in revista

<https://link.springer.com/article/10.2165%2F11317130-0000000000-00000>

Link catre articolul raportat in format pdf

[Cytokine antagonists](#)

49. **Antoniou SA.** Mepolizumab for difficult-to-control asthma with persistent sputum eosinophilia. Expert Opin Investig Drugs 2009 18(6):869-871, [IF= 4.21](#)

Link catre articolul raportat in revista

<https://www.tandfonline.com/doi/abs/10.1517/13543780902922678?journalCode=ieid20>

Link catre articolul raportat in format pdf

[Mepolizumab for difficult to control asthma](#)

50. **Antoniou SA**, Kolb MRJ. Update on models of pulmonary fibrosis therapy for preclinical drug research. Expert Opinion on Drug Discovery 2009 4(9): 939-946 **IF= 1.35**

Link catre articolul raportat in revista

<https://www.tandfonline.com/doi/abs/10.1517/17460440903186100?journalCode=iedc20>

Link catre articolul raportat in format pdf

[Update on models](#)

51. **Antoniou SA**. Discontinued drugs 2007: pulmonary, allergy, dermatological, gastrointestinal and arthritis drugs. Expert Opin Investig Drugs. 2008 17(11):1651-1661, ISSN: 1354-3784, **IF= 4.05**

Link catre articolul raportat in revista

<https://www.tandfonline.com/doi/abs/10.1517/13543784.17.11.1651?journalCode=ieid20>

Link catre articolul raportat in format pdf

[Discontinued drugs 2007](#)

52. **Antoniou SA**. Targeting endothelin pathway in the idiopathic pulmonary fibrosis: the role of bosentan. Expert Opin Ther Targets. 2008 12(9):1077-1084 **IF= 4.03**

Link catre articolul raportat in revista

<https://www.tandfonline.com/doi/abs/10.1517/14728222.12.9.1077?journalCode=iet20>

Link catre articolul raportat in format pdf

[TargetingIPFBosentan](#)

53. **Antoniou SA**, Mihalţan F, Ulmeanu R. Anti-TNF-alpha therapies in chronic obstructive pulmonary diseases. Expert Opin Investig Drugs. 2008 17(8):1203- 1211, **IF= 4.05**

Link catre articolul raportat in revista

<https://www.tandfonline.com/doi/abs/10.1517/13543784.17.8.1203?journalCode=ieid20>

Link catre articolul raportat in format pdf

[AntitnfalfaCOPD](#)

54. **Antoniou SA**. Bosentan for the treatment of idiopathic pulmonary fibrosis. Expert Opin Investig Drugs 2008 17(4): 611-614, ISSN: 1354-3784, **IF= 4.05**

Link catre articolul raportat in revista

<https://www.tandfonline.com/doi/abs/10.1517/13543784.17.4.611>

Link catre articolul raportat in format pdf

[BosentanIPF](#)

55. **Antoniou SA**, Mihaescu, T, Donner CF. Pharmacotherapy of cough-variant asthma. Expert Opin Pharmacother 2007 8(17): 3012-3018 **IF= 1.70**

Link catre articolul raportat in revista

<https://www.tandfonline.com/doi/abs/10.1517/14656566.8.17.3021?journalCode=ieop20>

Link catre articolul raportat in format pdf

[Cough variant asthma](#)

56. **Antoniou SA**. Infliximab for the therapy of chronic sarcoidosis. Expert Opin Investig Drugs. 2007 16(5):753-756, **IF= 3.66**

Link catre articolul raportat in revista

<https://www.tandfonline.com/doi/abs/10.1517/13543784.16.5.753?journalCode=ieid20>

Link catre articolul raportat in format pdf

[Infliximab sarcoidosis](#)

57. **Antoniou SA**, Mihaescu T, Donner CF. Inhaled therapy for stable chronic obstructive pulmonary disease. Expert Opin Pharmacother 2007 8(6): 777-785 **IF=1.70**

Link catre articolul raportat in revista

<https://www.tandfonline.com/doi/abs/10.1517/14656566.8.6.777?journalCode=ieop20>

Link catre articolul raportat in format pdf

[Inhaled therapy COPD](#)

58. **Antoniou SA**. Formoterol as a rescue medication for asthma. Expert Opin Pharmacother 2006 7(17): 2439-2441 **IF=1.73**

Link catre articolul raportat in revista

<https://www.tandfonline.com/doi/abs/10.1517/14656566.7.17.2439?journalCode=ieop20>

Link catre articolul raportat in format pdf

[Formoterol asthma](#)

59. **Antoniou SA**. Etanercept for refractory asthma therapy. Expert Opin Investig Drugs 2006 15(10): 1279-128, **IF= 3.17**

Link catre articolul raportat in revista

<https://www.tandfonline.com/doi/abs/10.1517/13543784.15.10.1279>

Link catre articolul raportat in format pdf

[Etanercept refractory asthma](#)

60. **Antoniou SA**. Sildenafil for pulmonary arterial hypertension: when blue turns into white. Expert Opin Pharmacother 2006 7(13): 1801-1810 **IF= 1.73**

Link catre articolul raportat in revista

<https://www.tandfonline.com/doi/abs/10.1517/14656566.7.13.1801?journalCode=ieop20>

Link catre articolul raportat in format pdf

[SildenafilPAH](#)

61. **Antoniou SA**. Daily versus intermittent corticosteroids for the treatment of mild persistent asthma. Expert Opin Pharmacother 2006 7(9):1235-8, **IF=1.73**

Link catre articolul raportat in revista

<https://www.tandfonline.com/doi/abs/10.1517/14656566.7.9.1235?journalCode=ieop20>

Link catre articolul raportat in format pdf

[Daily corticosteroids asthma](#)

62. **Antoniou SA**. Sildenafil citrate for the treatment of pulmonary arterial hypertension. Expert Opin Pharmacother 2006 7(6):825-8 **IF= 1.73**

Link catre articolul raportat in revista

<https://www.tandfonline.com/doi/abs/10.1517/14656566.7.6.825?journalCode=ieop20>

Link catre articolul raportat in format pdf

[Sildenafil citrate for PAH](#)

63. **Antoniou SA.** Pirfenidone for the treatment of idiopathic pulmonary fibrosis: therapeutic potential prompts further investigation. Expert Opin Investig Drugs 2005 14(11) : 1443-1447, [IF= 3.26](#)

Link catre articolul raportat in format pdf

[PirfenidoneIPF](#)

Link catre articolul raportat in revista

<https://www.tandfonline.com/doi/abs/10.1517/13543784.14.11.1443?journalCode=ieid20>

2. STANDARD MINIMAL ARTICOLE ISI COAUTOR

Domeniul Medicină, Farmacie: 5 articole, publicate pe parcursul întregii activități

RAPORTARE ARTICOLE ISI COAUTOR

(listă, cu link-urile corespunzătoare pentru verificare, active)

1. Alexa I, Alexa-Stratulat T, Antoniu S, Antohe I, Arghir O, Grigorescu C. Roflumilast in patients with advanced chronic obstructive pulmonary disease: towards a better-targeted use. Expert Opin on Pharmacother_ 2019 20 (1): 91-93, [IF-2.87](#)

Link catre articolul raportat in revista

<https://www.tandfonline.com/doi/abs/10.1080/14656566.2018.1544244?journalCode=iop20>

Link catre articolul raportat in format pdf

[RoflumilastCOPD](#)

2. Zaharie, AM; Antoniu, S; Wynimko, Chorostowska J, Mihltan F, Deleanu o, Mahler B, Davidescu L, Arghir OC, Ulmeanu R. Romanian Pilot Study of Alpha-1 Antitrypsin Detection-Feasibility and Challenges REVISTA DE CHIMIE_ 69 (5): 1152-5, [IF-1.6](#)

Link catre articolul raportat in revista

<https://revistadechimie.ro/Articles.asp?ID=6279>

Link catre articolul raportat in format pdf

[Alpha-1 antitrypsine](#)

3. Rajnoveanu R, Rajnoveanu A, Antoniu S, Todea DA, Man MA, Davidescu L, Valeanu M, Groza AT, Sfirlea VG, Ulmeanu R. Work-related stress factors and coping behavior among pneumologists. Acta Medica Mediterranea 2020 36(5): 2893-2899, [IF=0.24 pt 2019](#)

Link catre articolul raportat in revista

<https://www.actamedicamediterranea.com/archive/2020/medica-5/work-related-stress-factors-and-coping-behaviour-among-pneumologists/document>

Link catre articolul raportat in format pdf

[Work stress](#)

4. Rajnoveanu R, Rajnoveanu A, Ardelean AB, Todea DA, Pop CM, Antoniu S, Motoc NS, Chis AF, , Fildan AP, Man MA Pulmonologists Adherence to the Chronic Obstructive Pulmonary Disease GOLD Guidelines: A Goal to Improve MEDICINA-LITHUANIA 56 (9) Article Number: 422, [IF= 1.2 pt 2019](#)

Link catre articolul raportat in revista

<https://www.mdpi.com/1010-660X/56/9/422>

Link raportat in format pdf

[Adherence GOLD](#)

5. Azoicai T, **Antoniou SA**, Caruntu ID, Azoicai D, Antohe I, Gavrilovici C. Belimumab and antipneumococcal vaccination in patients with systemic lupus erythematosus. Expert review of clinical immunology 2018 Volume: 14 Issue: 3 Pages: 175-177, [IF=3.90](#)
Link catre articol raportat in revista

<https://www.tandfonline.com/doi/abs/10.1080/1744666X.2018.1429269?journalCode=ierm20>
Link catre articol raportat in format pdf
[Belimumab lupus](#)
6. Gavrilovici C, Luca A, **Antoniou SA**, Gallaby K, Stefanescu R, Starcea M, Miron I, Bild V. How nephrotoxic is the cancer therapy in children ? **Farmacia** 2018, 66(2): 197-208, [IF=1.52](#),
Link catre articolul raportat in revista
[http://www.revistafarmacia.ro/201802/art-01-Gavrilovici Luca Bild 197-208.pdf](http://www.revistafarmacia.ro/201802/art-01-Gavrilovici_Luca_Bild_197-208.pdf)
Link catre articolul raportat in format pdf
[Nephrotoxicity in cancer therapy](#)
7. Antohe, I. **Antoniou SA**, Gavrilovici C. Triple fixed inhaled therapy in frequent chronic obstructive pulmonary disease exacerbators: potential advantages for various degrees of airways obstruction. Expert Opinion on Pharmacotherapy 2018 Volume: 19 Issue: 3 Pages: 287-289, [IF=3.03](#)
Link catre articolul raportat in revista
<https://www.tandfonline.com/doi/abs/10.1080/14656566.2017.1419186?journalCode=iop20>
Link catre articolul raportat in format pdf
[Triple fixed in COPD](#)
8. Carone M, **Antoniou S**, Baiardi P, Digilio VS, Jones PW, Bertolotti G; QuESS Group. Predictors of Mortality in Patients with COPD and Chronic Respiratory Failure: The Quality-of-Life Evaluation and Survival Study (QuESS): A Three-Year Study. **COPD**. 2016;13(2):130-8. [IF=2.57](#)

Link catre articolul raportat in revista
<https://www.tandfonline.com/doi/abs/10.3109/15412555.2015.1067294?journalCode=icop20>
Link catre articolul raportat in format pdf
[QuESS study](#)
9. Otelea MR, Arghir O, Zugravu C, Naghi E, Antoniu S, Rascu A. Lung Function and Quality of Life in Workers with Chemical and Dust Exposure Revista de Chimie **2018** Volume: 69 Issue: 2 Pages: 346-349, [IF =1.60](#)

Link catre articolul raportat in revista
<https://revistadechimie.ro/Articles.asp?ID=6104>
Link catre articolul raportat in format pdf
[Lung function and quality of life](#)

3. STANDARD MINIMAL FACTOR CUMULAT DE IMPACT*

*se calculează ca sumă a factorilor de impact a revistelor în care au fost publicate articolele în calitate de autor principal, în anul apariției articolului
Domeniul Medicină, Farmacie: 10

RAPORTARE FACTOR CUMULAT DE IMPACT

(cifră, calculată conform indicațiilor, cu link-urile corespunzătoare pentru verificare, active)

1. [IF pentru 2019=2.87 Smoking cessation](#)
2. [IF pentru 2019=3.57 Checkpoint inhibitors](#)
3. [IF pentru 2019=2,87 Pulmonary alveolar proteinosis](#)
4. [IF pentru 2019=2,87 Revefenacin](#)
5. [IF=1.514 Extrarespiratory symptoms](#)
6. [IF=4.03 Investigational inhaled therapies](#)
7. [IF =3.97 Benralizumab](#)
8. [IF=4.03 Lebrikizumab](#)
9. [IF=1.78 Palliative care outcome](#)
10. [IF=2.74 Impact fatigue](#)
11. [IF=2.21 Nivolumab for advanced non-small lung cancer](#)
12. [IF=3.54 Combined Inhaled antibiotic](#)
13. [IF=1.64 Measuring fatigue](#)
14. [IF=5.13 Targeting 5-lipoxygenase-activating protein](#)
15. [IF=1.36 Asthma and pregnancy](#)
16. [IF=5.52 Bedoradrine for treating asthma](#)
17. [IF:2.24 Immune therapies for mesothelioma](#)
18. [IF=3.74 Epratuzumab for lupus](#)
19. [IF=1.66 Outcome measures for palliative oxygen](#)
20. [IF=1.66, Health status during hospitalisations](#)
21. [IF=1.87 Outpatient palliative care](#)
22. [IF= 5.43 Discontinued drugs for pulmonary, allergy](#)
23. [IF=1.87 Hospitalisations COPD](#)
24. [IF=5.43 Ciprofloxacin DPI in non-cystic fibrosis bronchiectasis](#)
25. [IF=3.08 Evaluation of inhaled tiotropium in asthma](#)
26. [IF=3.65 Monoclonal antibodies for asthma and COPD](#)
27. [IF=3.65 Tralokinumab in asthma](#)
28. [IF=5.43 Aeroquin for Pseudomonas aeruginosa](#)
29. [IF: 4.13 Targeting PDGF PAH](#)
30. [IF=4.74 Discontinued drugs 2011](#)
31. [IF: 4.13 Targeting RhoAROCK](#)
32. [IF: 4.86 Inhaled colistin](#)
33. [Impact factor 3.20 Varenicline for smoking cessation](#)
34. [IF= 5.27 Discontinued drugs 2010](#)
35. [IF= 3.43 Therapeutic approaches angioedema](#)
36. [IF=3.20 Inhaled gentamicin](#)
37. [IF= 3.20 Tiotropium in asthma](#)
38. [IF= 2.40 Triple inhaled COPD earlier](#)
39. [IF= 3.27 Pitrakinra for asthma](#)
40. [IF= 3.27 GM-CSF in PAP](#)
41. [IF= 3.64, Targeting TNF sarcoidosis](#)
42. [IF= 2.09 BiomarkersCOPD](#)
43. [IF= 1.84 Novel therapies for hypereosinophilic](#)
44. [IF=4.21 Fudosteine effects on mucin production](#)
45. [IF= 4.21 Discontinued drugs 2008](#)
46. [IF= 4.21 Daclizumab asthma](#)
47. [IF= 2.01 Itraconazole for severe asthma](#)

48. [IF= 3.5 Cytokine antagonists](#)
49. [IF= 4.21 Mepolizumab for difficult to control asthma](#)
50. [IF= 1.35 Update on models](#)
51. [IF= 4.05 Discontinued drugs 2007](#)
52. [IF= 4.03 Targeting IPF Bosentan](#)
53. [IF= 4.05 Antitnfalfa COPD](#)
54. [IF= 4.05 Bosentan IPF](#)
55. [IF= 1.70 Cough variant asthma](#)
56. [IF= 3.66 Infliximab sarcoidosis](#)
57. [IF= 1.70 Inhaled therapy COPD](#)
58. [IF= 1.73 Formoterol asthma](#)
59. [IF= 3.17 Etanercept refractory asthma](#)
60. [IF= 1.73 Sildenafil PAH](#)
61. [IF= 1.73 Daily corticosteroids asthma](#)
62. [IF= 1.73 Sildenafil citrate for PAH](#)
63. [IF= 3.26 Pirfenidone IPF](#)

[FCIAP suma de 1-63=202.314](#)

4. STANDARD MINIMAL INDICE HIRSCH*

Domeniul Medicină = 6

*conform ISI Web of Science, Core Collection, Thomson Reuters

RAPORTARE INDICE HIRSCH

(cifră, cu link-urile corespunzătoare pentru verificare, active)

Indice Hirsch(print screen): [14](#)

25.01.2021

Conf. Dr. Sabina Antonela Antoniu

